SCHEDULE 13D/A: BML Investment Partners Reduces Stake in AN2 Therapeutics to 10.7%

BML Investment Partners, L.P. has filed an amended Schedule 13D, disclosing a reduction in its beneficial ownership of AN2 Therapeutics, Inc. common stock to 10.7% following recent sales.

Summary

• BML Investment Partners, L.P. (the "Reporting Person"), managed by Braden M. Leonard, has amended its Schedule 13D filing regarding its stake in AN2 Therapeutics, Inc.
• The amendment was triggered by the sale of shares, with the event date being May 28, 2025.
• The Reporting Person's beneficial ownership in AN2 Therapeutics, Inc. has decreased to 3,217,423 shares, representing 10.7% of the Common Stock.
• Previously, BML Investment Partners, L.P. beneficially owned 3,649,432 shares, or 12.1% of the Issuer's Common Stock.
• Sales transactions occurred on May 28, 2025, and May 30, 2025, totaling 2,532,000 shares.
• The shares were acquired for investment purposes using working capital, and the Reporting Persons continuously evaluate the Issuer's businesses, results of operations, and prospects.
• The Reporting Persons reserve the right to acquire or dispose of additional securities of the Issuer at any time.

Sentiment

Score: 3

Explanation: The sentiment is moderately negative as a significant shareholder has reduced their stake, which can be perceived as a lack of confidence or a strategic divestment, potentially signaling a negative outlook for the company's stock price.

Positives

• The Reporting Persons acquired shares using working capital, indicating direct investment without external financing dependencies.
• The Reporting Persons continuously evaluate the Issuer's business, results, and prospects, suggesting active oversight of their investment.

Negatives

• BML Investment Partners, L.P. significantly reduced its stake in AN2 Therapeutics, Inc. from 12.1% to 10.7%, which could be perceived as a decrease in confidence by a major investor.
• The sales involved a substantial number of shares, totaling 2,532,000 shares across multiple transactions in late May 2025.

Risks

• The Reporting Persons reserve the right to acquire or dispose of additional securities at any time, which could lead to further volatility in the Issuer's stock price depending on their future actions.

Future Outlook

The Reporting Persons state they continuously evaluate the Issuer and reserve the right to acquire or dispose of additional securities of the Issuer at any time, or to formulate other purposes, plans, or proposals regarding the Issuer or its securities, based on investment policies, market conditions, or other factors.

Industry Context

This filing reflects a change in a significant institutional investor's position in a publicly traded biotechnology or pharmaceutical company (AN2 Therapeutics, Inc.). Such changes can influence market perception, particularly in sectors where investor confidence and long-term holding periods are crucial. The reduction in stake by a major holder might be viewed in the context of broader market trends, specific company performance, or the investor's portfolio rebalancing strategies.

Legal Proceedings

• None of BML Investment Partners, L.P., BML Capital Management, LLC, or Braden M. Leonard have been convicted in a criminal proceeding or a party to a civil proceeding related to federal or state securities laws in the past five years.

Stakeholder Impact

• Shareholders: The reduction in stake by a major investor could lead to decreased investor confidence and potential downward pressure on the stock price.
• Company Management: May need to address market concerns arising from the significant shareholder's divestment.

Next Steps

• The Reporting Persons may acquire or dispose of additional securities of AN2 Therapeutics, Inc. at any time.
• The Reporting Persons may formulate other plans or proposals regarding the Issuer or its securities.

Key Dates

Keywords

AN2 Therapeutics, BML Investment Partners, Schedule 13D, Beneficial Ownership, Stock Sales, Investment Management, SEC Filing, Common Stock, Shareholder Activity